FDA OKs first biosimilar of Roche’s blockbuster AMD drug Lucentis
pharmaphorum
SEPTEMBER 20, 2021
The approval comes a few weeks after the biosimilar was cleared for marketing in the EU with a broader label, as it also includes diabetic macular oedema (DMO), another of Lucentis’ approved indications. Sales reached a peak in 2019, when Roche booked $1.8 billion in sales from the drug while Novartis made $2.1 billion and $1.9
Let's personalize your content